Kathmere Capital Management, LLC Eli Lilly & CO Transaction History

Kathmere Capital Management, LLC

$798 Million
Q2 2024

A detailed history of Kathmere Capital Management, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Kathmere Capital Management, LLC holds 4,871 shares of LLY stock, worth $4.45 Million. This represents 0.55% of its overall portfolio holdings.

Number of Shares

4,871

Previous 4,647 4.82%

Holding current value

$4.45 Million

Previous $3.62 Million 21.99%

% of portfolio

0.55%

Previous 0.42%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 01, 2024	BUY	$724.87 - $909.04 $162,370 - $203,624	224 Added 4.82%	4,871 $4.41 Million
Q1 2024 Apr 16, 2024	SELL	$592.2 - $792.28 $132,652 - $177,470	-224 Reduced 4.6%	4,647 $3.62 Million
Q4 2023 Apr 16, 2024	BUY	$525.19 - $619.13 $1,050 - $1,238	2 Added 0.04%	4,871 $2.84 Million
Q3 2023 Oct 11, 2023	BUY	$434.7 - $599.3 $324,286 - $447,077	746 Added 18.09%	4,869 $2.62 Million
Q2 2023 Jul 11, 2023	BUY	$350.74 - $468.98 $15,783 - $21,104	45 Added 1.1%	4,123 $1.93 Million

Q1 2023 Apr 20, 2023	SELL	$310.63 - $364.82 $157,800 - $185,328	-508 Reduced 11.08%	4,078 $1.4 Million
Q4 2022 Jan 24, 2023	BUY	$321.55 - $374.67 $30,868 - $35,968	96 Added 2.14%	4,586 $0
Q4 2022 Jan 24, 2023	BUY	$321.55 - $374.67 $314,154 - $366,052	977 Added 27.81%	4,490 $0
Q3 2022 Oct 11, 2022	BUY	$296.48 - $337.87 $243,706 - $277,729	822 Added 30.55%	3,513 $1.14 Million
Q2 2022 Aug 09, 2022	BUY	$278.73 - $327.27 $362,070 - $425,123	1,299 Added 93.32%	2,691 $873,000
Q1 2022 Apr 28, 2022	SELL	$234.69 - $291.66 $238,210 - $296,034	-1,015 Reduced 42.17%	1,392 $399,000
Q3 2020 Nov 13, 2020	BUY	$146.22 - $169.13 $351,951 - $407,095	2,407 New	2,407 $356,000

Others Institutions Holding LLY

# of Institutions

3,725

Shares Held

738M

Call Options Held

7.09M

Put Options Held

7.24M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $869B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kathmere Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kathmere Capital Management, LLC with notifications on news.

Account

Kathmere Capital Management, LLC Eli Lilly & CO Transaction History